~~<i id='D72933B7BE'><strike id='D72933B7BE'><tt id='D72933B7BE'><pre id='D72933B7BE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：explore 2025-09-06 04:39:22 - browse：12489

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

entertainment

explore

knowledge

focus

leisure time

ChrisViehbachertookoverasBiogenCEOinNovember.SuzanneKreiter/Globestaff;PhotoillustrationAlexHogan/ST

WSS

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Colorectal cancer study finds potential in overlooked immune cell

After Optum profits sink, UnitedHealth makes changes

FDA authorizes Novavax’s updated Covid

FDA panel signals lack of confidence in Amgen cancer drug data

After Optum profits sink, UnitedHealth makes changes

hotspot

fashion

entertainment

Medical leaders decry Supreme Court decision on affirmative action

AI can decode, harness the power of the humane immune system

Dobbs anniversary: the lost opportunity of abortion as health care

A virus, fished out of a lake, may have saved a man’s life

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Analysis of telehealth claims data suggest service duplication

Duchenne breakthrough therapy leaves behind pioneering families

Bird flu researchers hone in on Finland’s mink farms

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The future of health care in the House

explore

Sana to lay off nearly a third of staff, de

Phenylephrine and the overlooked value of the placebo effect

Chemotherapy drug shortage eases slightly but still widespread

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA rejects Alnylam's heart disease treatment over insufficient data

Timeline: How the deadly wildfires took over Maui day by day

knowledge

focus

leisure time

leisure time